Get to know our clinical trials
Unblinded, randomized, pivotal study of the concomitant use of tumor-targeted electric fields (TTFields, 150 kHz) with pembrolizumab and platinum-based chemotherapy for the treatment of metastatic non-small-cell lung cancer
THE AIM OF THIS STUDY IS TO EVALUATE THE EFFICACY AND SAFETY OF TTFIELDS TOGETHER WITH THE REFERENCE TREATMENT, PEMBROLIZUMAB AND PLATINUM-DERIVED CHEMOTHERAPY.
Specialist
Medical Oncology Department
Navarre headquarters
Technical Summary
- UNBLINDED, RANDOMIZED, PIVOTAL STUDY OF THE CONCOMITANT USE OF TUMOR-TARGETED ELECTRIC FIELDS (TTFIELDS, 150 KHZ) WITH PEMBROLIZUMAB AND PLATINUM-BASED CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER
- Code EudraCT: -
- Protocol number: EF-44
- Promoter: NovoCure Ltd
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.